- Trial phase
- Approved (commercial); Phase 3 pediatric studies completed
- Time to market
- Already approved and commercially marketed. A pediatric PAH label expansion is possible but its filing/decision timing is unconfirmed in available data.
- Why 3/10
- No hard, dated binary is confirmed for OPSUMIT within the next ~12 months, the latest FDA actions on record are routine embryo-fetal-toxicity safety-labeling updates (May–June 2026), a pediatric PAH label-expansion filing/PDUFA is NOT confirmed in available data, and OPSUMIT is a small franchise product inside a mega-cap, so the score is capped at 3 (approved/commercializing, no pending regulatory decision evidenced).
Watch for a J&J/Janssen announcement of a pediatric PAH supplemental filing for OPSUMIT, the two supporting Phase 3 pediatric studies (TOMORROW, n=165, and a 7-patient Japanese study) have completed with posted results, so a submission would be the logical next binary, but no PDUFA date is evidenced yet. For a stock trading at $262.37 with a 22-analyst mean target of $272.50 (6.7% implied upside), OPSUMIT-specific news historically moves JNJ by well under ±1-2%, so treat any headline as franchise color, not a swing factor.
Price Chart
Executive Summary
OPSUMIT (macitentan) is an approved, marketed oral PAH drug developed by Actelion and now owned by Johnson & Johnson (JNJ) through its Janssen arm, confirmed this session by internal trial records listing Actelion and Janssen Pharmaceutical K.K. as sponsors with JNJ as the affected ticker. It is a mature franchise product inside a mega-cap, with completed Phase 3 pediatric trials suggesting a possible label expansion, but no hard regulatory decision is evidenced in the next 12 months. Net read: a steady, low-volatility product with no near-term binary, neutral for JNJ shareholders.
How It Works
OPSUMIT (macitentan) is an oral drug that blocks the action of endothelin, a chemical messenger that tightens blood-vessel walls. In pulmonary arterial hypertension (PAH), a rare disease of abnormally high blood pressure in the lung arteries, this relaxes and widens those vessels, easing the heart's workload. It is part of a class called endothelin receptor antagonists; it is taken once a day by mouth, and because it can harm a developing fetus, it carries a boxed warning restricting use in women who could become pregnant.
Trial Status
Two Phase 3 pediatric PAH studies are COMPLETED with results posted on ClinicalTrials.gov: TOMORROW (NCT02932410, 165 enrolled, sponsored by Actelion, completed 2025-11-27, primary completion 2024-08-28) and a Japanese pediatric study (NCT05167825, 7 enrolled, sponsored by Janssen Pharmaceutical K.K. [JNJ], completed 2025-03-05). The most recent FDA records are safety-labeling updates (May 20 and June 10-11, 2026) reaffirming the embryo-fetal-toxicity boxed warning for macitentan, standard for this drug class, not a new safety signal for the compound.
The Two-Sided Case
Upcoming Catalysts
- Possible J&J/Janssen announcement of a pediatric PAH supplemental application for OPSUMIT (unconfirmed timing) following completed Phase 3 pediatric trials
- Quarterly J&J earnings disclosures of pulmonary-hypertension franchise sales (next reports in 2026)
- Any FDA action on macitentan labeling (routine safety updates have been the only recent FDA records)
- Watch for competitor readouts in PAH that could pressure franchise share
Source Filing
The SecBot filing or press-release report that triggered this drug report:
JOHNSON & JOHNSON 8-K JNJ ·Originating report